符合中国糖尿病管理需求的胰高糖素样肽-1受体激动剂降糖新视角  

The New Perspective of GLP-1 Receptor Agonists Meeting the Requirements of Diabetes Management in China

作　　者：张芃子 毕艳[1] ZHANG Peng-zi;BI Yan(Department of Endocrinology,DrumTower Hospital Affiliated to Nanjing University Medical School,Nanjing Jiangsu 21008,China)

机构地区：[1]南京鼓楼医院内分泌科,江苏南京210008

出　　处：《药品评价》2020年第S01期15-18,27,共5页Drug Evaluation

摘　　要：中国糖尿病患者人数众多,控制率低下,一直是糖尿病管理的难点。因此,我们迫切需要改进降糖管理的手段,选择一种能够有效降糖且不增加低血糖风险,同时兼顾减重作用的优质治疗方案。新型降糖药物胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1 RA)具有降低糖化血红蛋白(glycosylated hemoglobin,HbA1C)水平,提高HbA1C达标率,减轻体重且不增加低血糖风险,同时还具有降低血压、改善血脂等效应,符合我国糖尿病管理多重获益的需求。The large number of diabetic patients and the low control rate in China have always been the difficulties of diabetes management.Therefore,we need to improve the methods of lowering blood glucose urgently and choose a high-quality treatment plan that can effectively lower blood glucose without increasing the risk of hypoglycemia and can reduce body weight at the same time.Glucagon-like peptide-1 receptor agonists(GLP-1 RAs),a new type of antihyperglycemic drugs,can deminish the level of glycosylated hemoglobin(HbA1C),increase the rate of achieving the goal of HbA1c without increasing the risk of hypoglycemia and reduce body weight.This class of drugs also has the effects of lowering blood pressure and improving blood lipids.So GLP-1 RAs can meet the needs of multiple benefits for diabetes management in China.

关 键 词：2型糖尿病 GLP-1受体激动剂 疗效 低血糖 减重 

分 类 号：R587.1[医药卫生—内分泌]